Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial.

Vipul Jairath, Silvio Danese, Geert R D'Haens, Brian G Feagan, Laurent Peyrin-Biroulet, Bruce E Sands, Ingrid Gaemers, Matt Westfall, Allyson Q Terry, Kevin J Roberts, Sara Barbat, Pamela Wedel, Jacqueline M Benson, Carlos Sattler